Clinical effects of low-molecular-weight heparin combined with ulinastatin in children with acute pancreatitis

Han, Ahram; Guo, Yonglang; Yin, Hua-Zhen

doi:10.4314/tjpr.v15i8.27

Trop. J. Pharm Res

2016

DOI: 10.4314/tjpr.v15i8.27

|View full text |Cite

Clinical effects of low-molecular-weight heparin combined with ulinastatin in children with acute pancreatitis

Ahram Han¹,

Yonglang Guo²,

Hua-Zhen Yin³

Abstract: 15 ± 1.50 S, 2.50 ± 0.50, 39.80 ± 5.90, and 192 ± 37 × 10 9 /L)). APACHE II scores and CTSPN after 2 weeks of treatment in the observation group were 8.50 ± 1.80 and 2.10 ± 1, respectively, which were superior to those in the control group (9.60 ± 2.40 and 4.30 ± 2.60, respectively; p < 0.05

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Non-Anticoagulant Activities of Low Molecular Weight Heparins—A Review

Feng,

Wang,

Zhou

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Low molecular weight heparins (LMWHs) are derived from heparin through chemical or enzymatic cleavage with an average molecular weight (Mw) of 2000–8000 Da. They exhibit more selective activities and advantages over heparin, causing fewer side effects, such as bleeding and heparin-induced thrombocytopenia. Due to different preparation methods, LMWHs have diverse structures and extensive biological activities. In this review, we describe the basic preparation methods in this field and compare the main principles and advantages of these specific methods in detail. Importantly, we focus on the non-anticoagulant pharmacological effects of LMWHs and their conjugates, such as preventing glycocalyx shedding, anti-inflammatory, antiviral infection, anti-fibrosis, inhibiting angiogenesis, inhibiting cell adhesion and improving endothelial function. LMWHs are effective in various diseases at the animal level, including cancer, some viral diseases, fibrotic diseases, and obstetric diseases. Finally, we briefly summarize their usage and potential applications in the clinic to promote the development and utilization of LMWHs.

show abstract

Non-Anticoagulant Activities of Low Molecular Weight Heparins—A Review

Feng,

Wang,

Zhou

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical effects of low-molecular-weight heparin combined with ulinastatin in children with acute pancreatitis

Cited by 1 publication

References 12 publications

Non-Anticoagulant Activities of Low Molecular Weight Heparins—A Review

Non-Anticoagulant Activities of Low Molecular Weight Heparins—A Review

Contact Info

Product

Resources

About